Objectives
Dysphagia is a common debilitating clinical feature of inclusion body myositis (IBM). However, the impact of dysphagia in IBM has been historically overlooked. This study aimed to identify, evaluate, and summarize the evidence regarding assessment and management of dysphagia in persons with IBM undergoing treatment.
Methods
A systematic review was conducted using a multi-engine search following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Eligible studies had to employ an intervention for persons with IBM, report a swallowing outcome, and be published in English. Quality assessments of the eligible studies were performed.
Results
Of 239 studies found, 19 met inclusion criteria. One study was rated as “fair” and the rest as “poor” quality, particularly due to the lack of published and validated swallowing assessment procedures and outcome measures. Cricopharyngeal (CP) dysfunction (12/19) was the most commonly reported swallowing abnormality. Interventions for disease management included pharmacological agents (10/19), followed by surgical (3/19), behavioral (1/19), and combined approaches (5/19). Interventions with immunosuppressants, Botox injection, balloon dilation, and/or CP myotomy led to mixed and transient benefit. Few studies examining statins or behavioral therapies (primarily focused on respiratory function) showed no effects for dysphagia.
Conclusion
Various interventions have been reported to temporarily improve dysphagia in persons with IBM. However, these findings are based on limited and overall low-quality evidence. This study cautions the generalization of these findings and emphasizes the need for further systematic research to improve diagnosis and management of dysphagia in IBM.